BIOLASE, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-11-13: Form 8-K; Period of report 2018-11-13; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2018-11-01: Form 8-K; Period of report 2018-10-26; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2018-10-09: Form 8-K; Period of report 2018-10-08; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; Details 5.02.
- 2018-10-03: Form 8-K; Period of report 2018-09-27; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-11-13 | 8-K | 2018-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2018, BIOLASE, Inc. issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2018. | biol-8k_20181113.htm |
| 2018-11-01 | 8-K | 2018-10-26 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d628611d8k.htm |
| 2018-10-09 | 8-K | 2018-10-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure | 5.02 On October 8, 2018, the Board of Directors (the “Board”) of Biolase, Inc. (the “Company”) elected Elaine C. Wagner to the Board. 5.03 On October 8, 2018, the Board approved an amendment to the Company’s bylaws, effective immediately upon approval by the Board. | d635475d8k.htm |
| 2018-10-03 | 8-K | 2018-09-27 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d634078d8k.htm |
| 2018-09-27 | 8-K | 2018-09-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 As described in Item 5.07 below, at a meeting held on September 21, 2018 (the “Special Meeting”), the stockholders of BIOLASE, Inc. (the “Company”) approved Amendment No. 1 to the BIOLASE, Inc. 2018 Long-Term Incentive Plan (the “2018 Plan Amendment”), which had been previously approved by the Company’s Board of Directors (the “Board”), subject to stockholder approval. 5.07 On September 21, 2018, the Company held its Special Meeting. | d629951d8k.htm |
| 2018-09-26 | 8-K | 2018-09-26 | 7.01 Regulation FD Disclosure | 7.01 On September 26, 2018, John R. Beaver, Executive Vice President and Chief Financial Officer of Biolase, Inc. (the “Company”) delivered a presentation at the Sidoti & Company Fall 2018 Investor Conference that included a written communication comprised of slides. | d628202d8k.htm |
| 2018-09-05 | 8-K | 2018-09-04 | 7.01 Regulation FD Disclosure | 7.01 On September 4, 2018, John R. Beaver, Executive Vice President and Chief Financial Officer of Biolase, Inc. (the “Company”) delivered a presentation at the Rodman & Renshaw 20th Annual Global Investment Conference that included a written communication comprised of slides. | d619109d8k.htm |
| 2018-08-08 | 8-K | 2018-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2018, BIOLASE, Inc. issued a press release announcing its financial results for the second quarter and six months ended June 30, 2018. | biol-8k_20180808.htm |
| 2018-08-08 | 8-K | 2018-08-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On August 7, 2018, Biolase, Inc. (the “Company”) entered into an employment agreement with Todd Norbe to serve as President and Chief Executive Officer of Biolase, effective August 7, 2018. | biol-8k_20180807.htm |
| 2018-06-22 | 8-K/A | 2018-06-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 In a Current Report on Form 8-K filed on June 19, 2018 (the "Original 8-K"), Biolase, Inc. (the "Company") disclosed the election of Messrs. | htm_56246.htm |
| 2018-06-19 | 8-K | 2018-06-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On June 15, 2018, the Board of Directors (the "Board") of Biolase, Inc. (the "Company") elected Jess Roper and Todd Norbe to the Board. 7.01 On June 19, 2018, the Company issued a press release announcing the election of Messrs. | htm_56235.htm |
| 2018-05-11 | 8-K | 2018-05-10 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 As previously announced, on May 9, 2018, the stockholders of BIOLASE, Inc., a Delaware corporation (the “Company”) approved a proposal at the 2018 annual meeting of stockholders (the “Annual Meeting”) to amend the Company’s Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect a reverse stock split of the Company’s common stock, par value $0.001 (“Common Stock”), at a ratio ranging from one-for-five (1:5) to one-for-fifteen (1:15), with the final ratio to be determined by the Board of Directors (the “Board”). | d585361d8k.htm |
| 2018-05-10 | 8-K | 2018-05-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.02 As described in Item 5.07 below, at a meeting held on May 9, 2018 (the “Annual Meeting”), the stockholders of BIOLASE, Inc. (the “Company”) approved the BIOLASE, Inc. 2018 Long-Term Incentive Plan (the “2018 Plan”), which had been previously approved by the Company’s Board of Directors (the “Board”), subject to stockholder approval. 5.07 On May 9, 2018, the Company held its Annual Meeting. 8.01 On May 10, 2018, the Company issued a press release announcing that, at the Annual Meeting, the Company’s stockholders approved a proposal to amend the Company’s Restated Certificate of Incorporation to effect a reverse stock split of Company common stock at a ratio of not less than 1-for-5 and not more than 1-for-15, with the final ratio to be determined by the Board. | d583765d8k.htm |
| 2018-05-03 | 8-K/A | 2018-04-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As previously reported, effective April 10, 2018, Harold C. Flynn, Jr. resigned as President and Chief Executive Officer and as a director of the Company. | htm_56112.htm |
| 2018-05-02 | 8-K | 2018-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2018, BIOLASE, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2018. | biol-8k_20180331.htm |
| 2018-04-13 | 8-K | 2018-04-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Harold C. Flynn, Jr., a Company Director, and the Company's President and Chief Executive Officer, resigned as a Director and as the Company's President and Chief Executive Officer, effective April 10, 2018. | htm_56045.htm |
| 2018-04-10 | 8-K | 2018-04-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On April 4, 2018, the Board of Directors (the "Board") of Biolase, Inc. (the "Company") elected Garrett Sato to the Board. | htm_56036.htm |
| 2018-03-14 | 8-K | 2018-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2018, BIOLASE, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2017. | biol-8k_20180314.htm |
| 2018-03-12 | 8-K | 2018-03-06 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d496041d8k.htm |